Xilio Therapeutics Announces Promotion Of Chris Frankenfield To Chief Operating Officer
Portfolio Pulse from Benzinga Newsdesk
Xilio Therapeutics, Inc. (NASDAQ:XLO) has promoted Chris Frankenfield to the position of Chief Operating Officer. Frankenfield has over 15 years of experience in the biotechnology sector and has previously served as Xilio's Chief Legal and Administrative Officer and General Counsel. Prior to joining Xilio, he held positions at Blueprint Medicines and PricewaterhouseCoopers LLP.
August 04, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chris Frankenfield's promotion to Chief Operating Officer at Xilio Therapeutics could potentially strengthen the company's strategic initiatives and operations, given his extensive experience in the biotech sector.
Chris Frankenfield's extensive experience in the biotech sector, including his previous roles at Xilio and other companies, could potentially strengthen Xilio's strategic initiatives and operations. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100